Polymorphisms of the epidermal growth factor receptor (EGFR) and survival in patients with advanced cancer of the head and neck (HNSCC)

Anticancer Research

Volumn 32, Issue 2, 2012, Pages 421-425

  Stoehlmacher Williams, Jan ^a   Obermann, Luise ^a   Ehninger, Gerhard ^a   Goekkurt, Eray ^b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Cetuximab; EGFR polymorphism; Head and neck cancer; PCR RFLP; SNPs

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ALLELE; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DNA EXTRACTION; FEMALE; GENOTYPE; HAZARD RATIO; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; CISPLATIN; FEMALE; GENOTYPE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE;

EID: 84856845213     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Schlessinger J: Cell signaling by receptor tyrosine kinases. Cell 103: 211-225, 2000.
2. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW and Burgess AW: Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 284: 31-53, 2003. (Pubitemid 36331965)
3. Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, Kish JA, McClure S, VonFeldt E and Williamson SK: Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 10: 1245-1251, 1992.
4. Gibson MK, Li Y, Murphy B, Hussain MH, DeConti RC, Ensley J and Forastiere AA: Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E 1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 23: 3562-3567, 2005.
5. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK and Ang KK: Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11: 21-28, 2010.
6. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N and Hitt R: Platinumbased chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359: 1116-1127, 2008.
7. Liu W, Innocenti F, Chen P, Das S, Cook EH Jr and Ratain MJ: Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin Cancer Res 9: 1009-1012, 2003. (Pubitemid 36323704)
8. Liu W, Innocenti F, Wu MH, Desai AA, Dolan ME, Cook EH Jr and Ratain MJ: A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res 65: 46-53, 2005. (Pubitemid 40070794)
9. Liu W, Wu X, Zhang W, Montenegro RC, Fackenthal DL, Spitz JA, Huff LM, Innocenti F, Das S, Cook EH Jr, Cox NJ, Bates SE and Ratain MJ: Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. Clin Cancer Res 13: 6788-6795, 2007. (Pubitemid 350206817)
10. Brandt B, Meyer-Staeckling S, Schmidt H, Agelopoulos K and Buerger H: Mechanisms of egfr gene transcription modulation: relationship to cancer risk and therapy response. Clin Cancer Res 12: 7252-7260, 2006. (Pubitemid 46095396)
11. Moriai T, Kobrin MS, Hope C, Speck L and Korc M: A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling. Proc Natl Acad Sci USA 91: 10217-10221, 1994. (Pubitemid 24311980)
12. Klinghammer K, Knödler M, Schmittel A, Budach V, Keilholz U and Tinhofer I: Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Clin Cancer Res 16: 304-310, 2010.
13. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P and Ferguson KM: Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7: 301-311, 2005. (Pubitemid 40544648)
14. Krohn V, Wiegand S, Werner JA and Mandic R: EGFR codon 497 polymorphism - implications for receptor sensitivity to inhibitors in HNSCC cell lines. Anticancer Res 31: 59-65, 2011.
15. Rizzo S, Bronte G, Fanale D, Corsini L, Silvestris N, Santini D, Gulotta G, Bazan V, Gebbia N, Fulfaro F and Russo A: Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild-type status required for antiEGFR therapy? Cancer Treat Rev 36(Suppl 3): 56-61, 2010.
16. Pirker R, Paz Ares L, Eberhardt W, Krzakowski M, Störkel S, Heeger S, von Heydebreck A, Stroh C and O'Byrne KJ: EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small cell lung cancer (NSCLC): analyses of data form the phase 3 FLEX study. Lancet doi 10 1016/S1470-2945(11)70318-7, 2011.
17. Sharafinski ME, Ferris RL, Ferrone S and Grandis JR: Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck 32: 1412-1421, 2010.
18. Bruckman KC, Schönleben F, Qiu W, Woo VL and Su GH: Mutational analyses of the BRAF, KRAS, and PIK3CA genes in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 110: 632-637, 2010.
19. Tinhofer I, Klinghammer K, Weichert W, Knödler M, Stenzinger A, Gauler T, Budach V and Keilholz U: Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Clin Cancer Res 17(15): 5197-5204, 2011.
20. López-Albaitero A, Lee SC, Morgan S, Grandis JR, Gooding WE, Ferrone S and Ferris RL: Role of polymorphic Fc gamma receptor IHa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother 58: 1853-1864, 2009.